New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Ramsey Baghdadi
Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
Trump’s Big Missed Opportunity: Medicare For All
With control over all branches of government, President Trump and Republicans made a choice to pursue repeal of the ACA and tax cuts over a strategy that could have redefined the party: Medicare For All with competitive private sector principles.
HHS Senior Advisor O’Brien Emerges As Azar’s Lead On Drug Pricing In 2019
O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.
Louisiana Purchase: State Eager To Test “Netflix Model” For Rx Spending
A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?
REDUCE-IT Will Test Risks Of Weakening Protection Of FDA-Labeled Claims
Amarin spent five years and lots of money to show Vascepa reduced the risk of cardiovascular events. REDUCE-IT trial results will test what Amarin will get for conducting the trial and whether the company’s off-label argument could work against them.
Medicare's CAR-T Panel Underscores Hurdles For PROs – And FDA/CMS Collaboration
MEDCAC meeting demonstrates complexity of patient-reported outcomes and place for PROs in regulatory decision-making compared to coverage.
Subsys Makes A Bad Impression On FDA REMS Panel Members
CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.
Advertisement